Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Summer Interns Arrive At Herman B Wells Center For Pediatric Research
Twenty-nine students arrived at Indiana University School of Medicine"s Herman B Wells Center for Pediatric Research to work a 10-week summer internship alongside top pediatric researchers. More than 250 applicants vied for the treasured research spots. Most of the candidates come from Indiana universities.

"What Must EPS Pilot Prove?" Asks NPA
The NPA is asking its members to utilise the new NPA IT forums website to comment on the criteria that should be used to demonstrate that EPS is operationally functional ahead of national roll-out. The NPA believes that EPS must work technically, be business and operationally functional, improve service delivery at pharmacies, and is safe for patients, before full roll-out can be contemplated. The website, http://itforums.npa.co.uk, provides an opportunity for members throughout the UK to voice their opinions on the IT programmes affecting their country or on general IT topics which affect all nations.
News of the day
Study Highlights Massive Imbalances In Global Fertilizer Use
Synthetic fertilizers have dramatically increased food production worldwide. But the unintended costs to the environment and human health have been substantial. Nitrogen runoff from farms has contaminated surface and groundwater and helped create massive "dead zones" in coastal areas, such as the Gulf of Mexico. And ammonia from fertilized cropland has become a major of air pollution, while emissions of nitrous oxide form a potent greenhouse gas.
Public Health

HRA Pharma Granted European Marketing Authorization For EllaOne(R) - Next Generation Emergency Contraceptive

HRA Pharma, a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate), its next generation emergency contraceptive, has been granted marketing authorization by the European Commission. The unanimous decision by all member states enables HRA Pharma to begin marketing ellaOne throughout the European Union, making it the only approved product to have been specifically designed and developed for use as an emergency contraceptive. "This milestone is testimony to emergency contraception as a real therapeutic need and to the potential of ulipristal acetate as a viable solution," said Dr. Erin Gainer, CEO of HRA Pharma. "Our goal is to ensure that ellaOne is available to the millions of women who might need it, and we plan to put our sales and marketing infrastructure as well as our privileged partnerships into action to accompany this roll-out." The European Commission"s marketing authorization follows the positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency in March 2009. ellaOne will be progressively launched and marketed throughout the entire European Union, directly by HRA Pharma in the UK, Germany, Italy and France and via partner companies elsewhere. Current hormonal emergency contraception (based on levonorgestrel) is very well tolerated, but its efficacy decreases significantly as time elapses after unprotected intercourse. Based on the new chemical entity ulipristal acetate, ellaOne has been shown to have sustained efficacy and has thus been approved for use up to five days after unprotected intercourse, without compromising the safety or tolerability profile of levonorgestrel. HRA Pharma has long been a leader in emergency contraception, providing solutions to unmet needs for millions of women in over 50 countries since the launch of its pioneering product NorLevo. The company plans to file for marketing approvals in countries worldwide under the trademarks ellaOne and ella, and continues to research pharmaceutical developments in the field of reproductive health that are better adapted to women"s lifestyles. HRA Pharma is currently developing its compound ulipristal acetate for other indications outside of emergency contraception, including uterine fibroids. HRA Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009